Evidence map›Paper›PMID 41159231›Full record

ReviewRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2025

Therapeutic optimization against bacteria carrying metalloenzymes: the battle for class B.

Manuel Pina-Sánchez, Marta Rua, Francisco Javier Candel, José Luis Del Pozo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Manuel Pina-SánchezDepartment of Clinical Microbiology, Clínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0002-6960-7236
Marta RuaDepartment of Clinical Microbiology, Clínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0002-4727-0660
Francisco Javier CandelClinical Microbiology and Infectious Diseases. IdISSC & IML Health Research Institutes. Hospital Clínico Universitario San Carlos, Madrid. Spain.ORCID 0000-0002-9840-6556
José Luis Del PozoDepartment of Clinical Microbiology, Clínica Universidad de Navarra, Pamplona, Spain.ORCID 0000-0002-5402-3334

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The spread of metallo-β-lactamases (MBL)-producing Gram-negative bacilli represents a global health challenge, associated with increased mortality rates. The prevalence of MBL-producing isolates, particularly of New Delhi metallo-β-lactamase (NDM) subclass, is increasing globally. The optimal antibiotic for infections depends on the species and MBL subclass produced. Currently, the antimicrobial cornerstones against these pathogens are aztreonam/avibactam and cefiderocol. Successful therapy requires the early and adequate initiation of antibiotic treatment, optimisation of its pharmacokinetics/pharmacodynamics, and appropriate control of the infection source.

Indexed as

Anti-Bacterial Agentsbeta-LactamasesGram-Negative BacteriaGram-Negative Bacterial InfectionsAztreonamCefiderocolCephalosporinsHumansAnti-Bacterial AgentsAztreonambeta-LactamasesCefiderocolCephalosporinsAztreonam/avibactamCarbapenem resistanceCefiderocolGram-negative bacteriaMBL inhibitorsMetallo-β-lactamase

Identifiers

PMID41159231
PMCPMC12584911

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.